Filing Details
- Accession Number:
- 0001209191-21-036143
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2021-05-27 06:00:22
- Reporting Period:
- 2021-05-17
- Accepted Time:
- 2021-05-27 06:00:22
- Original Submission Date:
- 2021-05-19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1564824 | Allakos Inc. | ALLK | Pharmaceutical Preparations (2834) | 454798831 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1608782 | Robert Alexander | 975 Island Drive, Suite 201 Redwood City CA 94065 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-05-19 | 14,516 | $98.94 | 245,395 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-05-19 | 14,516 | $0.69 | 259,911 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-05-18 | 14,517 | $102.32 | 245,395 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-05-18 | 14,517 | $0.69 | 259,912 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-05-17 | 14,517 | $99.68 | 245,395 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-05-17 | 14,517 | $0.69 | 259,912 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-05-19 | 5,482 | $98.89 | 336,750 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2021-05-18 | 5,484 | $102.29 | 342,232 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2021-05-17 | 5,484 | $99.69 | 347,716 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to buy) | Disposition | 2021-05-19 | 14,516 | $0.00 | 14,516 | $0.69 |
Common Stock | Stock Option (Right to buy) | Disposition | 2021-05-18 | 14,517 | $0.00 | 14,517 | $0.69 |
Common Stock | Stock Option (Right to buy) | Disposition | 2021-05-17 | 14,517 | $0.00 | 14,517 | $0.69 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
956,050 | 2021-05-19 | No | 4 | M | Direct | |
970,566 | 2021-05-18 | No | 4 | M | Direct | |
985,083 | 2021-05-17 | No | 4 | M | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. This transaction was executed in multiple trades at prices ranging from $97.84 to $100.68 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan.
- Includes 7,905 shares received as a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners Management VIII, LLC (APM VIII), without consideration, to the Reporting Person as a non-managing member of APM VIII.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. This transaction was executed in multiple trades at prices ranging from $100.75 to $104.55 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. This transaction was executed in multiple trades at prices ranging from $97.29 to $100.91 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2021. This transaction was executed in multiple trades at prices ranging from $97.53 to $100.48 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- The shares are held by Mr. Alexander and Stacey Lee Alexander, as Trustees of the Alexander 2018 Irrevocable Descendants' Trust.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2021. This transaction was executed in multiple trades at prices ranging from $100.84 to $104.54 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2021. This transaction was executed in multiple trades at prices ranging from $97.23 to $100.63 per share. The sale price reported represents the weighted average sale price. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- On May 17, 2017, the Reporting Person was granted an option to purchase 1,412,800 ordinary shares pursuant to the Company's 2012 Equity Incentive Plan. The option vests as to one-fourth of the shares on May 17, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.